Document is current
Any future updates will be listed below
-
Authors
Junker, Kerstin https://orcid.org/0000-0002-0873-8128
Hallscheidt, Peter
Wunderlich, Heiko
Hartmann, Arndt
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 6 April 2021
Accepted: 18 February 2022
First Online: 16 March 2022
Declarations
:
: Kerstin Junker: Stockholder: Novartis Pharma GmbH, Bayer AG; Honoraria for lectures: IPSEN Pharma GmbH, Pfizer Pharma GmbH; Financial support of research projects: IPSEN Pharma GmbH. Peter Hallscheidt: No conflicts of interest. Heiko Wunderlich: Honoraria for lectures or consulting/advisory boards for Bristol Myers Squibb, IPSEN Pharma GmbH, Janssen, MSD Sharp&Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche; Coordinating Investigator: Cabocare-Study (NIS) by IPSEN Pharma GmbH. Arndt Hartmann: Honoraria for lectures or consulting/advisory boards for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech and other research support from AstraZeneca, Biontech, Cepheid, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche.
: Not applicable.
: Not applicable.
